Androxal enclomiphene: Phase II data

The single-blind, U.S. Phase II ZA-204 trial in 48 evaluable men with morning testosterone levels of <350 ng/dL showed that once-daily Androxal

Read the full 224 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE